Ranbaxy Laboratories, India’s largest pharmaceutical company, has completed 20 successful years in Russia. The company established its operations in the Russian market in 1993 with the launch of its key brand, Cifran. Since then, Ranbaxy has grown to become a No 1 player with a market share of 15.4% in the represented market segment in Russia, as per IMS, May 2013.
With a well-established distribution network and skilled field force, Ranbaxy presently has operations in 56 regions in Russia and has built strong equity with its customers. The company has a portfolio of products covering anti-infective, cold, pain management, cardiovascular, diabetology, central nervous system, urology and dermatology segments. The company has so far registered 51 drugs in the Russian Federation and commercialized 72 SKU’s.
Ranbaxy’s leading brands in Russia includes Ketanov, Coldact, Faringosept, Cifran, Pylobact and Fenules. Last year, the company’s popular brand, Faringosept was selected as the People’s brand of choice. Another well know brand, Cifran OD was ranked by IMS as the best antibiotic launch in 2004.
With a well-established distribution network and skilled field force, Ranbaxy presently has operations in 56 regions in Russia and has built strong equity with its customers. The company has a portfolio of products covering anti-infective, cold, pain management, cardiovascular, diabetology, central nervous system, urology and dermatology segments. The company has so far registered 51 drugs in the Russian Federation and commercialized 72 SKU’s.
Ranbaxy’s leading brands in Russia includes Ketanov, Coldact, Faringosept, Cifran, Pylobact and Fenules. Last year, the company’s popular brand, Faringosept was selected as the People’s brand of choice. Another well know brand, Cifran OD was ranked by IMS as the best antibiotic launch in 2004.
No comments:
Post a Comment